Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;30(2):e14420.
doi: 10.1111/cns.14420. Epub 2023 Aug 29.

Homocysteine and Parkinson's disease

Lingyan Zhou  1
Affiliations
Review

Homocysteine and Parkinson's disease

Lingyan Zhou. CNS Neurosci Ther. 2024 Feb.

Abstract

Homocysteine (Hcy) is an important metabolite in methionine metabolism. When the metabolic pathway of homocysteine is abnormal, it will accumulate in the body and eventually lead to hyperhomocysteinemia. In recent years, many studies have found that hyperhomocysteinemia is related to the occurrence and development of Parkinson's disease. This study reviews the roles of homocysteine in the pathogenesis of Parkinson's disease and illustrates the harmful effects of hyperhomocysteinemia on Parkinson's disease.

Keywords: Parkinson's disease; homocysteine; hyperohomocysteinemia.

PubMed Disclaimer

Conflict of interest statement

The authors report no declarations of interest.

Figures

FIGURE 1
FIGURE 1
The metabolic pathway of methionine and homocysteine. 5‐MTHF, 5‐methyl tetrahydrofolate; BLMH, bleomycin hydrolase; BPHL, mitochondrial bisphenol hydrolase‐like; CBS, Cystathionine β‐synthase; CGL, cystathionine γ‐lyase; Hcy, homocysteine; HTL, homocysteine thiolactone; MARS, Methionine‐tRNA synthetase; MAT, Methionine S‐adenosyltransferase (MAT); Met, methionine; MS, Methionine synthase; MTHFR, 5, 10‐methylene tetrahydrofolate reductase; PON1, paraoxonase‐1; SAH, S‐adenosylhomocysteine; SAM, S‐adenosylmethionine; THF, tetrahydrofolate.
See this image and copyright information in PMC

References

    1. Surguchov A. In: Peplow PV, Martinez B, Gennarelli TA, eds. Neurodegenerative Diseases Biomarkers: Towards Translating Research to Clinical Practice. Springer US; 2022:155‐180.
    1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397:2284‐2303. doi:10.1016/S0140-6736(21)00218-X - DOI - PubMed
    1. GBD 2016 Neurology Collaborators . Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:459‐480. doi:10.1016/S1474-4422(18)30499-X - DOI - PMC - PubMed
    1. Rocca WA. The future burden of Parkinson's disease. Mov Disord. 2018;33:8‐9. doi:10.1002/mds.27114 - DOI - PMC - PubMed
    1. Rocca WA. The burden of Parkinson's disease: a worldwide perspective. Lancet Neurol. 2018;17:928‐929. doi:10.1016/S1474-4422(18)30355-7 - DOI - PubMed